By Fineline Cube 
Sanofi (NASDAQ: SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the subcutaneous (SC) formulation of Sarclisa (isatuximab) for multiple myeloma treatment across both relapsed/refractory (R/R MM) and newly diagnosed (NDMM) settings. The approval marks Japan’s adoption of the innovative CirCLIQ on-body injector (OBI) delivery system, making Sarclisa SC the first anticancer therapy administered via this technology in the Japanese market.
Regulatory Approval Details
| Parameter | Detail |
|---|---|
| Regulatory Agency | MHLW (Japan) |
| Product | Sarclisa (isatuximab) subcutaneous formulation |
| Delivery System | CirCLIQ on-body injector (OBI) |
| Approved Combinations | • Pomalidomide + dexamethasone (Pd) • Carfilzomib (for R/R MM) • Bortezomib + lenalidomide + dexamethasone (VRd) (for NDMM) |
| Indications | Relapsed/refractory MM and newly diagnosed MM |
| Approval Basis | IRAKLIA Phase 3 study (NCT05405166) + supportive studies |
Clinical Evidence & Delivery Innovation
- IRAKLIA Phase 3 Study: Demonstrated non-inferiority of SC formulation compared to intravenous (IV) administration in R/R MM patients
- CirCLIQ Technology: First anticancer treatment globally to utilize the on-body injector system, reducing administration time from hours (IV) to minutes (SC)
- Patient Convenience: Enables outpatient or at-home administration potential, significantly improving treatment experience and healthcare resource utilization
- Global Validation: Previously approved in EU and UK, with Japan representing the first major Asian market adoption
Market Impact & Strategic Significance
- Japanese Myeloma Burden: Approximately 7,500 new multiple myeloma cases annually in Japan, with aging population driving increased incidence
- Treatment Paradigm Shift: SC formulation addresses significant unmet need for convenient, time-efficient administration in a disease requiring chronic therapy
- Competitive Differentiation: Positions Sarclisa ahead of other anti-CD38 monoclonal antibodies (daratumumab) that remain IV-only in Japan
- Commercial Expansion: Builds on Sarclisa’s existing presence in nearly 60 countries across four indications, strengthening Sanofi’s hematology franchise
Global Myeloma Treatment Landscape
The approval reinforces the trend toward subcutaneous delivery in oncology, following successful transitions of other monoclonal antibodies from IV to SC formulations. Sanofi’s investment in the CirCLIQ platform demonstrates commitment to patient-centric innovation beyond molecule development alone.
With multiple myeloma increasingly managed as a chronic condition requiring long-term therapy, administration convenience becomes a critical factor in treatment selection and patient adherence. The Japanese approval validates both the clinical equivalence and practical advantages of the SC formulation in a sophisticated, high-value market.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market opportunities, and commercial expectations. Actual results may differ due to market dynamics, competitive pressures, and healthcare policy changes.-Fineline Info & Tech